Clinical Evaluation of BW430C in Epilepsy
Clinical Evaluation of BW430C in Epilepsy
To evaluate safety information of BW430C when administered using the lower starting doses and
 slower dose escalations as recommended Global Data Sheet
Inclusion criteria:

 -  Epilepsy with partial seizures

 -  Tonic clonic seizures

 -  Generalized seizures of Lennox-Gastaut

 -  Subjects whose seizures are easily recognizable at least one seizure per month and
 counts for 8 consecutive weeks prior to the start of the study drug.

 -  Concurrent AEDs: Subjects taking concurrent VPA.

 Exclusion criteria:

 -  Previous participation in a study of Lamictal

 -  Known hypersensitivity to any drugs

 -  Pregnant women

 -  nursing mothers

 -  women who may be pregnant

 -  women contemplating pregnancy during the study period